HIV (human immunodeficiency virus) is a virus that damages the cells in your immune system and weakens your ability to fight everyday infections and disease.

SwiftDX Protein Colour
Global problem

HIV Remains a Widespread and Deadly Disease

HIV is a serious public health pandemic and management of this disease is one of the United Nation’s sustainable health goals. Worldwide, HIV remains the biggest killer of women of child bearing age. So far, HIV has claimed 40.1 million lives and could claim another 7.7 million over the next 10 years.
Most HIV infections are asymptomatic in the first five years of infection; while there is no cure, HIV treatment transforms the disease into a manageable chronic health condition. Early diagnosis, through rapid testing, prevents onward transmission and disease progression.

SwiftDX Protein Mole

Early HIV Rapid Detection

Need for early detection diagnostics

Point-of-care and self-testing PCR and lateral flow technologies currently rely on the detection of a person's immune response to HIV infection. This widens the window between infection and detection, during which a person is at their most infectious.

Current Rapid Diagnostics

Current LFAs are not sufficiently sensitive to directly detect HIV antigen and, therefore, can only detect infection after a person has generated an immune response. This can mean up to 12 weeks from infection to possible detection.


The global HIV testing effort was severely hampered by COVID-19. It is thought that the market will be worth more than USD 9B in 2030

SwiftDx Solution

By deploying eAMP technology, the SwiftDx early HIV detection test will be an ultra-boosted sensitivity dual antibody and antigen diagnostic that will close the possible testing window to as little as 14 days after infection.

Our affordable, easy to use and highly sensitive assay would be applicable in clinical settings as a point-of-care device and as a self-test application.